[Skip to Content]
[Skip to Content Landing]
March 16, 1984

Sulfadiazine: Therapeutic Evaluation and Toxic Effects on Four Hundred and Forty-six Patients

Author Affiliations

From the Thorndike Memorial Laboratory, Second and Fourth Medical Services (Harvard), Boston City Hospital, and the Department of Medicine, Harvard Medical School.

JAMA. 1984;251(11):1467-1474. doi:10.1001/jama.1984.03340350057031

Sulfadiazine (2-sulfanilamidopyrimidine), the pyrimidine analogue of sulfapyridine and sulfathiazole, is one of a group of heterocyclic derivatives of sulfanilamide synthesized by Roblin and his co-workers.1 Laboratory studies on animals indicated that this drug has less toxicity than sulfapyridine and sulfathiazole and is highly effective against experimental infections with common pathogens.2 Preliminary observations in this clinic3 and in a number of others in which sulfadiazine was made available4 indicated that this drug was worthy of extensive trial in the therapy of human bacterial infections. This paper deals mainly with a report of the clinical use of sulfadiazine in 446 adult patients treated at the Boston City Hospital prior to March 1, 1941. The results of laboratory studies will be reviewed briefly.

ANIMAL EXPERIMENTS  Feinstone and his associates2 have shown that sulfadiazine is considerably less toxic than sulfapyridine or sulfathiazole both in acute experiments on mice and